Mumbai: Sanofi India has announced that Rodolfo Hrosz, Managing Director of the Company, will step down from his current role effective April 30, 2025. The move comes as Hrosz prepares to transition ...

Dr Fox is a paid advisor to Sanofi for the HERCULES study. Erik Wallström, MD, PhD, global head of neurology development, said: “By targeting disability progression mechanisms behind the blood-brain ...

Sanofi India Limited announced on Wednesday that its Managing Director, Rodolfo Hrosz, will step down from his role effective April 30, 2025, to take up another position within the Sanofi group, the ...

At the American Academy of Neurology (AAN) 2025 Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with non-relapsing secondary progressive multiple ...

Credit: Kateryna Kon / Shutterstock. At the American Academy of Neurology (AAN) 2025 Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with ...

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in ...

On 7 April, Dalal Street saw a dramatic downturn as widespread panic-selling caused a steep decline in market valuations. A staggering ₹16 lakh crore in market value was wiped out—the most ...

An icon of 3 horizontal dots. An icon of a paper envelope. An icon of a facebook f logo. An icon of a digital camera. An icon of a house. An icon of the Instagram logo. An icon of the LinkedIn logo.

Supported by Sanofi. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. We thank the trial participants and their families and caregivers ...

One of the most polarising logos in sports. Irene Castle, McLaughlin’s wife, is credited with the original design of the logo, a side profile of an Aboriginal American, presumably Black Hawk ...

South Ko­re­an biotech ABL Bio has lined up an­oth­er plat­form li­cense agree­ment with a Eu­ro­pean phar­ma gi­ant in the area of neu­rode­gen­er­a­tive dis­eases.